Bone imaging cannot be safely omitted in advanced prostate cancer cases because no PSA level combined with T stage and Gleason Grade Group can accurately rule in bone metastases, a new study found.
For decades, it has been known that the mutations in the tumor suppressor genes BRCA1 and BRCA2 are associated with high risks of breast and ovarian cancer, but a new prospective cohort study provides the strongest evidence to date that these mutations are associated with the development of prostate cancer (PCa). The BRCA2 mutation appears…
The median time from first infusion of sipuleucel-T to death from prostate cancer was 42.7 months.
The new consensus statement reflects the advances made in glucose monitoring technology and offers guidance for clinicians.
Three doses of testosterone nasal gel may help normalize testosterone levels in men with hypogonadism.